← Leaderboards
Christine M Eischen
Thomas Jefferson University
$17,498,082
Attributed
$20,357,546
Total exposure
14
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,357,546 · 14
By mechanism
R01$19,519,237 · 11
P30$463,774 · 2
R21$374,535 · 1
Top collaborators
- David K Cortez5 shared
- Joseph M Salvino4 shared
- Richard T Pomerantz2 shared
Most similar at Thomas Jefferson University
Same institution · by research overlap
- Bruno Calabretta$9,620,602
- Alexander M Mazo$10,970,170
- Arthur M. Buchberg$5,281,617
- Antonio Giordano$4,608,769
- W Edward Mercer$1,500,236
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorPathway InteractionsProteinsTumorigenesisCellsApoptosisIn VivoMediatingLeadOncogenesMouse ModelInsightOverexpressionCancer CellTherapeutic InterventionDna DamageLymphomaInnovationIn VitroRegulationMutantOncogenicLink
Grant awards (64)
A Next-Generation Nucleoside Prodrug for Diffuse Large B-Cell Lymphoma$623,596
R01 · FY2025 · CA
Design of the First Mdm2 Targeting PROTACs for treatment of p53 Mutant or Deficient Cancers$544,697
R01 · FY2025 · CA
Investigating a new vulnerability in oral squamous cell carcinoma$521,948
R01 · FY2025 · DE · contact PI
BCLW in lymphoma survival and resistance to targeted BCL2 family therapies$364,182
R01 · FY2025 · CA · contact PI
Research Program: Immune Regulation Targets (IRT)$62,950
P30 · FY2025 · CA · contact PI
A Next-Generation Nucleoside Prodrug for Diffuse Large B-Cell Lymphoma$623,596
R01 · FY2024 · CA
Design of the First Mdm2 Targeting PROTACs for treatment of p53 Mutant or Deficient Cancers$515,157
R01 · FY2024 · CA
Investigating a new vulnerability in oral squamous cell carcinoma$511,509
R01 · FY2024 · DE · contact PI
BCLW in lymphoma survival and resistance to targeted BCL2 family therapies$355,240
R01 · FY2024 · CA · contact PI
Research Program: Immune Regulation Targets (IRT)$58,948
P30 · FY2024 · CA · contact PI
Investigating a new vulnerability in oral squamous cell carcinoma$535,846
R01 · FY2023 · DE · contact PI
Design of the First Mdm2 Targeting PROTACs for treatment of p53 Mutant or Deficient Cancers$529,097
R01 · FY2023 · CA
Replication stress in hematopoiesis and lymphomagenesis$419,436
R01 · FY2023 · CA · contact PI
BCLW in lymphoma survival and resistance to targeted BCL2 family therapies$112,885
R01 · FY2023 · CA · contact PI
Design of the First Mdm2 Targeting PROTACs for treatment of p53 Mutant or Deficient Cancers$558,144
R01 · FY2022 · CA
BCLW in lymphoma survival and resistance to targeted BCL2 family therapies$421,205
R01 · FY2022 · CA · contact PI
Replication stress in hematopoiesis and lymphomagenesis$419,436
R01 · FY2022 · CA · contact PI
Molecular Biology and Genetics$66,007
P30 · FY2022 · CA · contact PI
BCLW in lymphoma survival and resistance to targeted BCL2 family therapies$429,800
R01 · FY2021 · CA · contact PI
Replication stress in hematopoiesis and lymphomagenesis$427,995
R01 · FY2021 · CA · contact PI
Molecular Biology and Genetics$66,007
P30 · FY2021 · CA · contact PI
BCLW in lymphoma survival and resistance to targeted BCL2 family therapies$429,800
R01 · FY2020 · CA · contact PI
Replication stress in hematopoiesis and lymphomagenesis$427,995
R01 · FY2020 · CA · contact PI
Molecular Biology and Genetics$66,007
P30 · FY2020 · CA · contact PI
Replication stress in hematopoiesis and lymphomagenesis$427,995
R01 · FY2019 · CA · contact PI
Molecular Biology and Genetics$66,007
P30 · FY2019 · CA · contact PI
Novel oncogenic functions of Mdm2 and Mdmx$323,700
R01 · FY2018 · CA · contact PI
Novel mechanisms of oncogenic transformation in lung cancer$323,700
R01 · FY2018 · CA · contact PI
Molecular Biology and Genetics$66,007
P30 · FY2018 · CA · contact PI
Novel oncogenic functions of Mdm2 and Mdmx$26,400
R01 · FY2018 · CA · contact PI
Molecular Biology and Genetics$11,841
P30 · FY2018 · CA · contact PI
Novel mechanisms of oncogenic transformation in lung cancer$323,700
R01 · FY2017 · CA · contact PI
Novel oncogenic functions of Mdm2 and Mdmx$323,700
R01 · FY2017 · CA · contact PI
SMARCAL1 function in replication stress and disease$474,854
R01 · FY2016 · CA · contact PI
Novel mechanisms of oncogenic transformation in lung cancer$323,700
R01 · FY2016 · CA · contact PI
Novel oncogenic functions of Mdm2 and Mdmx$322,477
R01 · FY2016 · CA · contact PI
Myc-induced pathways in B cell lymphoma initiation and survival$169,650
R21 · FY2016 · CA · contact PI
SMARCAL1 function in replication stress and disease$473,092
R01 · FY2015 · CA · contact PI
Novel mechanisms of oncogenic transformation in lung cancer$255,870
R01 · FY2015 · CA · contact PI
Myc-induced pathways in B cell lymphoma initiation and survival$204,885
R21 · FY2015 · CA · contact PI
Novel oncogenic functions of Mdm2 and Mdmx$190,644
R01 · FY2015 · CA · contact PI
Regulation of Myc-Mediated Tumorigenesis$183,987
R01 · FY2015 · CA · contact PI
Regulation of Myc-Mediated Tumorigenesis$139,434
R01 · FY2015 · CA · contact PI
Novel oncogenic functions of Mdm2 and Mdmx$135,131
R01 · FY2015 · CA · contact PI
Novel mechanisms of oncogenic transformation in lung cancer$69,905
R01 · FY2015 · CA · contact PI
SMARCAL1 function in replication stress and disease$458,898
R01 · FY2014 · CA · contact PI
Novel oncogenic functions of Mdm2 and Mdmx$325,775
R01 · FY2014 · CA · contact PI
Novel mechanisms of oncogenic transformation in lung cancer$325,775
R01 · FY2014 · CA · contact PI
Regulation of Myc-Mediated Tumorigenesis$313,718
R01 · FY2014 · CA · contact PI
SMARCAL1 function in replication stress and disease$444,706
R01 · FY2013 · CA · contact PI
Regulation of Myc-Mediated Tumorigenesis$304,016
R01 · FY2013 · CA · contact PI
SMARCAL1 function in replication stress and disease$473,092
R01 · FY2012 · CA · contact PI
Regulation of Myc-Mediated Tumorigenesis$389,664
R01 · FY2012 · CA · contact PI
Regulation of Myc-Mediated Tumorigenesis$388,417
R01 · FY2011 · CA · contact PI
p53-Independent Pathways in Mdm2-Mediated Transformation$281,892
R01 · FY2011 · CA · contact PI
p53-Independent Pathways in Mdm2-Mediated Transformation$290,620
R01 · FY2010 · CA · contact PI
p53-Independent Pathways in Mdm2-Mediated Transformation$329,378
R01 · FY2009 · CA · contact PI
p53-Independent Pathways in Mdm2-Mediated Transformation$291,850
R01 · FY2008 · CA · contact PI
p53-Independent Pathways in Mdm2-Mediated Transformation$302,560
R01 · FY2007 · CA · contact PI
The Role of Mdm2 in Lymphoma Development$291,296
R01 · FY2007 · CA · contact PI
The Role of Mdm2 in Lymphoma Development$287,450
R01 · FY2006 · CA · contact PI
The Role of Mdm2 in Lymphoma Development$294,368
R01 · FY2005 · CA
The Role of Mdm2 in Lymphoma Development$314,769
R01 · FY2004 · CA
Mdm2 in Lymphoma Development$321,140
R01 · FY2003 · CA